AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01814410
Drug: Intravenous ethanol placebo plus nicotine infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
Trial: NCT01814410
Drug: intravenous ethanol 40mg% plus nicotine infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
Trial: NCT01814410
Drug: intravenous ethanol 100mg% plus nicotine infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
Trial: NCT01697800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02467361
Drug: BBI608
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.
Trial: NCT02360774
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
Trial: NCT01511783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
Trial: NCT00017368
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00017368
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03248882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02630563
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids will be administered as per center practice. The choice of corticosteroid drug will also be based on center practice.
Trial: NCT03476759
Drug: IVF/ICSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 patients will undergo IVF-ICSI procedures.
Trial: NCT00319709
Drug: SR58611A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01150578
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention
Trial: NCT00416819
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00416819
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01773083
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: Sterile saline nebulized 6 times daily for the maximum duration of 14 days
Trial: NCT03865927
Drug: GKT137831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GKT137831 is a NOX enzyme inhibitor
Trial: NCT04101383
Drug: RinGlar®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
Trial: NCT04101383
Drug: Lantus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
Trial: NCT00245024
Drug: sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02244047
Drug: Placebo (for Bifidobacterium breve)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00789620
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus 0.15 ml/kg NaCl 0.9% NaCl 0.2 ml/kg/h Perfusor NaCl 0.9% 0.13 ml/kg/h Perfusor
Trial: NCT01249417
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.M. injection on day 1 of a single treatment cycle.
Trial: NCT02760719
Drug: nebulized 3% hypertonic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: already described
Trial: NCT04365231
Drug: Hydroxychloroquine and azithromycin treatment
RxNorm normalized name: cefixime and azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.~- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days.
Trial: NCT00360425
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00427141
Drug: GSK580416
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00872521
Drug: PAD induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open Label Treatment:~Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 \& 11), Doxorubicin 20 mg/m2 i.v. (D1 \& 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 \& 12)
Trial: NCT02309970
Drug: acetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subject in this group will receive oral treatment with anti platelet drug
Trial: NCT03744637
Drug: MK-5475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single inhaled dose of MK-5475 120, 165, 240, 300, 360, or 480 ug depending upon randomization
Trial: NCT03744637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single inhaled dose of placebo to match MK-5475
Trial: NCT02871141
Drug: Antidepressant
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant
Trial: NCT02893384
Drug: Local Anesthetic Injection above the serratus anterior
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a quantitative pilot study assessing whether a new technique of local anesthesia injection during mastectomy surgery gives better pain outcomes than the standard methods. Patients who meet inclusion criteria will be invited to partake and all patients will have the injection technique. These patients will then be monitored for pain outcomes up to 7 days following the surgery and the results compared with historical results from patients who have already had the surgery.
Trial: NCT01064414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One matching placebo capsule orally once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
Trial: NCT02361112
Drug: pyrotinib combined with capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03131167
Drug: SHP639 (n=60)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug SHP639 is a 9-amino acid, synthetic, C-type natriuretic peptide (CNP) analog.
Trial: NCT03131167
Drug: Placebo Comparator (n=24)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Vehicle Ophthalmic placebo solution of the same composition as the test product.
Trial: NCT01167569
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic Acid/Placebo 10mg/kg body weight X2 in Operating Room followed by Ascorbic Acid/Placebo 5mg/kg x 48 hours.
Trial: NCT00002610
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002610
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01018238
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of placebo (no active ingredients) administered subcutaneously (under the skin)
Trial: NCT03428100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT03428100
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as standard-of-care.
Trial: NCT03861780
Drug: Project X 26ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of antiseptic drug to the inguinal and abdomen areas of the subjects
Trial: NCT03861780
Drug: Project X 5.1ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of antiseptic drug to the inguinal and abdomen areas of the subjects
Trial: NCT02884310
Drug: Remifentanil adapted to SPI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02884310
Drug: Remifentanil fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00750763
Drug: Colonlytely
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel preparation
Trial: NCT00750763
Drug: Picolax/Picoprep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel preparation
Trial: NCT02532335
Drug: Obeticholic acid placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT03746587
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule
Trial: NCT04351165
Drug: IMP4297
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP4297 10mg/capsule; IMP4297 20mg/capsule;
Trial: NCT02221648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomization to receive either the study drug or the placebo group.
Trial: NCT00371956
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tab 1 daily
Trial: NCT01222000
Drug: apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
Trial: NCT02711176
Drug: Tinafas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in experimental group will receive the 14 day single dose regimen of Tinafas 1 g daily
Trial: NCT02711176
Drug: Tavanex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in experimental group will receive the 14 day single dose of Tavanex 500 mg daily
Trial: NCT03878992
Drug: Genotropin miniquick 0.5 mg, injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH will be given as an injection. Muscle biopsy will be obtained from m. vests laterals of the dominant leg. Fat biopsies will be obtained from subcutaneous abdominal fat. Tracers will be given as a bolus followed by continuous infusion for 6 hours. For palmitate tracer the infusion will be for only 1,5 hours followed by a one hour break and then another 1 hour infusion. Blood tests will be drawn from a venous catheter placed on the dorsal side of the hand.
Trial: NCT02711176
Drug: Klacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in active comparator group will receive the 14 day clarithromycin (Klacid) 500 mg twice daily twice daily
Trial: NCT02711176
Drug: Iramox
RxNorm normalized name: pramoxine hydrochloride Topical Gel [Pramox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in active comparator group will receive the 14 day amoxicillin (Iramox) 1 g twice daily
Trial: NCT03639246
Drug: Pegylated liposomal doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD is active comparator
Trial: NCT00807885
Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution
Trial: NCT00062348
Drug: boronophenylalanine-fructose complex
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02236312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00327717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in placebo group were titrated with placebo in the same way as in zonisamide group.
Trial: NCT00719160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 20 mg twice a day for 9 days
Trial: NCT03059693
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01954238
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCC-4401C matching placebo(Capsule): Strength is not applicable. GCC-4401C and placebo will be administered double-blind after a 10 hours fast.
Trial: NCT01211145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray
Trial: NCT01205347
Drug: Simvastatin 80mg
RxNorm normalized name: SIMVASTATIN 80MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 80mg once a day
Trial: NCT01205347
Drug: Simvastatin 10mg
RxNorm normalized name: SIMVASTATIN 10MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 10mg once a day
Trial: NCT01518569
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (the same amount of normal saline) iv before the initiation of CPB
Trial: NCT00625456
Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Dosage from 1 x 10\^5 pfu/kg to 3 x 10\^7 pfu/kg Intravenous infusion is administered once over a 60 minute period
Trial: NCT01373151
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only
Trial: NCT01373151
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, Oral, 15 mg, Weekly, 48 weeks
Trial: NCT01373151
Drug: Methotrexate Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only
Trial: NCT01373151
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only
Trial: NCT00361452
Drug: nebulized epinephrine and nebulized albuterol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01190813
Drug: Levodopa/Carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Trial: NCT01190813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tid
Trial: NCT00325819
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
Trial: NCT00350103
Drug: SPM 929
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical form: Immediate release film-coated tablets~* Concentration: 50mg/ 100mg~* Route of administration: Oral use
Trial: NCT00350103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical form: Immediate release film-coated tablets~* Route of administration: Oral use
Trial: NCT03291821
Drug: GnRH analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH analog subcutaneously
Trial: NCT02801032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, matching capsule p.o. minimum one week apart from active treatment.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention.
Trial: NCT02367547
Drug: Aminolevulinic Acid Nano Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the study we use Ameluz.
Trial: NCT02367547
Drug: Methylaminolevulinate cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the study we use Metvix.
Trial: NCT04020419
Drug: PediaBerry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PediaBerry or placebo will be mixed with a cream vehicle for topical administration or with water for oral administration
Trial: NCT03257592
Drug: [11C]DPA-713
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[11C\]DPA-713 PET imaging
Trial: NCT03842904
Drug: Trimbow pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical Trial of an Investigational Medicinal Product (CTIMP)
Trial: NCT03842904
Drug: Fostair pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical Trial of an Investigational Medicinal Product (CTIMP)
Trial: NCT04178304
Drug: Prolotherapy with 25% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 6mL of 25% dextrose Extra-articular injection at tender sites with 25% dextrose
Trial: NCT00650819
Drug: Ezetimibe + Simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10 mg plus simvastatin 20 mg once daily for 8 weeks
Trial: NCT00650819
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 20 mg plus ezetimibe placebo once daily for 8 weeks
Trial: NCT00931203
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg/d) will be continued from day 1 to 65
Trial: NCT03749317
Drug: IVIEW-1201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIEW-1201; QID; one drop per eye, four times per day (QID) for 7 days
Trial: NCT03749317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug; QID; one drop per eye, four times per day (QID) for 7 days
Trial: NCT04311710
Drug: ENHANZE (rHuPH20)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified Dose on Specified Days
Trial: NCT03738423
Drug: REGN3500-Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneous (SC)
Trial: NCT00435175
Drug: estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00532909
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage: 1000mg/m2 By mouth twice a day for 14 days or reduced dose of 800mg/m2 PO BID days1-14.
Trial: NCT02315144
Drug: TV48108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TV48108 15, 60, 120 μg
Trial: NCT02315144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT01000987
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00214617
Drug: Rosuvastatin at 5 mg/day and 40 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02844634
Drug: Doxycycline 100mg PO daily x 12 months
RxNorm normalized name: infigratinib
DrugBank: Infigratinib (DB11886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate use of daily doxycycline (12 months duration, to start immediately)
Trial: NCT02844634
Drug: Doxycycline 100mg PO daily x 6 months
RxNorm normalized name: infigratinib
DrugBank: Infigratinib (DB11886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferred use of doxycycline (6 months duration, to start 6 months post-randomization)
Trial: NCT04206657
Drug: 1mg KHK7580
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose administration of 1mg KHK7580
Trial: NCT04206657
Drug: 3mg KHK7580
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose administration of 3mg KHK7580
Trial: NCT04206657
Drug: 6mg KHK7580
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose administration of 6mg KHK7580
Trial: NCT04206657
Drug: 12mg KHK7580
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose administration of 12mg KHK7580
Trial: NCT04206657
Drug: 6mg KHK7580 for 8days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple oral dose administration of 6mg KHK7580 for 8days
Trial: NCT02382510
Drug: TRN-157
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00150410
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02906163
Drug: SoC (tyrosine kinase inhibitor)
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Phase II patients will be randomized to SoC or Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 18 months.
Trial: NCT01546051
Drug: BCI-1038, BCI-1206 & BCI-1283
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design